Literature DB >> 10918340

Oestrogens and Alzheimer's disease.

M H Birkhäuser1, J Strnad, C Kämpf, M Bahro.   

Abstract

In the last decade, several reports suggest that oestrogen replacement therapy (ORT=ERT=estrogen replacement therapy) might prevent or delay Alzheimer's disease. Oestrogens influence and modulate brain structure and brain function. There are substantial arguments that the postmenopausal oestrogen loss might, together with other factors, accelerate the appearance of Alzheimer's disease. The evidence is suggestive, but not compelling, that ORT can reduce the relative risk to suffer from Alzheimer's disease. Furthermore, recent findings are consistent with the hypothesis that oestrogens might ameliorate the symptomatology in early stages of Alzheimer's disease. However, it has to be remembered that in most clinical trials the number of oestrogen users was quite small, and, usually, oestrogen use was not randomised. The aim of the present review is to discuss the data available today in view of their clinical relevance. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918340     DOI: 10.1002/1099-1166(200007)15:7<600::aid-gps155>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  2 in total

1.  Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide.

Authors:  A H Tammer; G Coia; R Cappai; S Fuller; C L Masters; P Hudson; J R Underwood
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  Sex differences in the incidence and prevalence of young-onset Alzheimer's disease: A meta-analysis.

Authors:  Geeske Peeters; Katerine Katelekha; Brian Lawlor; Naiara Demnitz
Journal:  Int J Geriatr Psychiatry       Date:  2021-08-12       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.